Table 3

Effects of PPAR ligands on AOM-induced ACF formation in male F344 rats (experiment 2)

Group no.Treatment (no. of rats examined)Body weight (g)Liver weight (g)Relative liver weight (g/100 g body weight)ACF/colonACs/focus
1AOM alone (12)166 ± 3a,b10.3 ± 1.44.73 ± 0.4983 ± 62.01 ± 0.24
2AOM + 0.01% troglitazone (8)172 ± 1110.8 ± 1.04.89 ± 0.4468 ± 161.66 ± 0.21
3AOM + 0.05% troglitazone (8)176 ± 5c11.1 ± 1.04.99 ± 0.2855 ± 13d1.54 ± 0.13e
4AOM + 0.01% bezafibrate (8)181 ± 5c12.3 ± 1.15.38 ± 0.2375 ± 81.97 ± 0.20
5AOM + 0.05% bezafibrate (8)178 ± 911.8 ± 0.54.88 ± 0.1953 ± 9c1.85 ± 0.10
60.05% troglitazone (4)194 ± 39.2 ± 0.84.72 ± 0.3600
70.05% bezafibrate (4)193 ± 912.3 ± 0.5f6.34 ± 0.14g00
8None (4)182 ± 69.0 ± 1.04.89 ± 0.3300
  • a Mean ± SD.

  • b Significantly different from group 8: P < 0.001;

  • c Significantly different from group 1: P < 0.001;

  • d Significantly different from group 1: P < 0.01; and

  • e Significantly different from group 1: P < 0.005.

  • f Significantly different from group 8: P < 0.05; and

  • g Significantly different from group 8: P < 0.01.